StockData

Ardelyx vs Travere Therapeutics

ARDX and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARDX and TVTX compare

Travere Therapeutics is the larger company, worth 6.1 times as much as Ardelyx ($4.8B against $792M).

Travere Therapeutics grew revenue faster over the last twelve months (77.1% versus 16.8% for Ardelyx).

Travere Therapeutics keeps more of each dollar of sales as profit, with a net margin of −7.4% compared with −12.4% at Ardelyx.

Ardelyx scores higher on the StockData Score (9 against 6 for Travere Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARDXTVTX
Size and price
Market cap$792M$4.8B
Share price$3.18$51.10
Change, 1 year−45.7%48.1%
Change, 5 years256%76.0%
Beta (5Y)1.091.91
Employees489497
StockData Score
Total score9 (better)6
Valuation score2 (better)0
Growth score33
Performance score3 (better)2
Health score11
Dividend score00
Valuation
P/S1.8× (better)8.1×
P/B5.3× (better)196×
EV/EBITDA–197×
FCF yield−2.3%–
Fair value$7.61$6.01
Margin of safety58.2% (better)−751%
Growth
Revenue growth (TTM)16.8%77.1% (better)
Revenue growth, 5Y average122% (better)19.9%
Profitability
Gross margin94.4%98.6% (better)
Operating margin−7.9%−6.8% (better)
Net margin−12.4%−7.4% (better)
FCF margin−4.0%–
Return on equity−38.6% (better)−152%
Financial health
Interest coverage−1.6× (better)−4.3×
Current ratio3.344.05 (better)
Altman Z-score−0.102.29 (better)
Piotroski F-score37 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions71.2%112%
Held by insiders6.9%1.6%
Insider net buying, 12 months−$1.9M (better)−$110M
Short interest, % of float12.6%10.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.